Analysis ReDS technology by use Health Technology Assessment modelling, quantity and optimization methods
Main Article Content
Keywords
health technology assessment., optimization, heart failure, medical device, remote dielectric sensing, outpatient level, inpatient level
Abstract
Background: The specificity of CHF is a high rate of recurrent hospitalizations for acute decompensation of heart failure (ADHF). One of the important aspects of monitoring the patient’s condition is monitoring the volemic status - identifying and determining the degree of stagnation for the timely optimization of the treatment regimen in order to prevent re-hospitalization. In this regard, of great interest is a new technology for non-invasive measurement of fluid levels in the lungs, implemented in a medical product under the ReDS brand (manufactured by Sensible Medical, Israel). ReDS™ (from remote dielectric sensing) technology is a quantitative, non-invasive method for measuring total lung fluid volume in patients with fluid drainage problems, including those with heart failure. It may be implemented at inpatient, outpatient and pharmacy levels. The results of the assessment showed that at a given level of implementation of ReDS technology, the number of readmissions at the inpatient level will decrease from 375 703 to 252 208 per year, and at the outpatient level from 375 703 to 252 208 per year. This corresponds to a decrease in the annual cost of recurrent hospitalizations from 24.93 billion rubles. respectively to 20.96 (by 15.9%) billion rubles. and 19.70 billion rubles. (21.0% reduction, including additional costs for patient visits to measure for ReDS). At the same time, one-time costs for the purchase of 1 234 units of a ReDS medical device for an outpatient level or 1 129 units of a ReDS medical device for an inpatient level amount to 12.06 billion rubles or 11.04 billion rubles, respectively. The results of the “budget impact” analysis (taking into account the discount factor of 3.5%) of the introduction of ReDS technology at the outpatient level demonstrate that over 7 years it provides cost savings in the amount of 20.33 billion rubles, up to 45.92 billion rubles, and at the stationary level – 13.61 billion rubles
References
2. Rossiya v cifrah. Kratkij statisticheskij sbornik. 2021
3. Hronicheskaya serdechnaya nedostatochnost. Klinicheskie rekomendacii. Ros kardiologj Zhur. 2020;25(11):4083. https://doi.org/10.15829/1560-4071-2020-4083
4. Bragazzi N, Zhong W, Shu J, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol. 2021;28(15):1682-90. https://doi.org/10.1093/eurjpc/zwaa147
5. Roger V. Epidemiology of Heart Failure: A Contemporary Perspective. Circ Res. 2021;128(10):1421-34. https://doi.org/10.1161/CIRCRESAHA.121.318172
6. Sajt Ministerstva Zdravoohraneniya RF 2022 Glavnyj kardiolog Minzdrava Rossii o prichinah razvitiya hronicheskoj serdechnoj nedostatochnosti. [Elektronnyj resurs]. Rezhim dostupa: https://minzdrav.gov.ru/news/2020/07/29/14573-glavnyykardiolog- minzdrava-rossii-o-prichinah-razvitiya-hronicheskoy-serdechnoy-nedostatochnosti Data obrashcheniya:20/10/2020
7. Polyakov D, Fomin I, Belenkov Y, et al. Hronicheskaya serdechnaya Nedostatochnost v Rossijskoj Federacii: chto izmenilos’ za 20 let nablyudeniya? Rezul’taty issledovaniya EPOHAHSN. Kardiologiya. 2021;61(4):4-14. https://doi.org/10.18087/ cardio.2021.4.n1628
8. Drapkina O, Bojcov S, Omel’yanovskij V, et al. Social’no-ekonomicheskij ushcherb, obuslovlennyj hronicheskoj serdechnoj nedostatochnost’yu, v Rossijskoj Federacii. Ros kardiologzhur. 2021;26(6):4490. https://doi.org/10.15829/1560-4071-2021- 4490
9. Zhuravleva M, Kukes V, Prokof’ev A, et al. Kliniko-ekonomicheskij analiz primeneniya innovacionnogo lekarstvennogo preparata sakubitril/valsartan v lechenii pacientov, stradayushchih hronicheskoj serdechnoj nedostatochnost’yu so snizhennoj frakciej vybrosa. RMZH. 2017;4:282-9.
10. Sattar Y, Zghouzi M, Suleiman A, et al. Efficacy of remote dielectric sensing (ReDS) in the prevention of heart failure rehospitalizations: a meta-analysis. J Community Hosp Intern Med Perspect. 2021;11(5):646-52. https://doi.org/10.1080/20009666.2021.1955451
11. Oshima A, Imamura T, Onoda H, Hori M, Kinugawa K. A novel therapeutic strategy:Remote dielectric sensing-guided management of pulmonary congestion. J Cardiol Cases. 2021;25(5):269-271. https://doi.org/10.1016/j.jccase.2021.10.009
12. Imamura T, Tanaka S, Ueno H, Kinugawa K. Remote Dielectric Sensing to Assess Residual Pulmonary Congestion Following Percutaneous Mitral Valve Repair. Medicina.2022;58(9):1292. https://doi.org/10.3390/medicina58091292
13. Rafique Z, McArthur R, Sekhon N, Mesbah H, Almasary A, Peacock W. Remote dielectric sensing for detecting pulmonary edema in the emergency department. Am J Emerg Med. 2022;55:11-15. https://doi.org/10.1016/j.ajem.2022.02.030
14. Uriel N, Sayer G, Imamura T, Rodgers D, et al. Relationship Between Noninvasive Assessment of Lung Fluid Volume and Invasively Measured Cardiac Hemodynamics. J of the Americ Heart Ass. 2018;7:e009175. https://doi.org/10.1161/ JAHA.118.009175
15. Amir O, Azzam Z, Gaspar T, Faranesh-Abboud S, Andria N, et al. Validation of remote dielectric sensing (ReDSTM) technology for quantification of lung fluid status: Comparison to high resolution chest computed tomography in patients with and without acute heart failure. Int J of Card. 2016;221:841-6. https://doi.org/10.1016/j.ijcard.2016.06.323
16. Amir O, Ben-Gal T, Weinstein J, Schliamser J, Burkhoff D, et al. Evaluation of remote dielectric sensing (ReDS) technologyguided therapy for decreasing heart failure re-hospitalizations. Int J of Card. 2017;240:279-84 http://dx.doi.org/10.1016/j.ijcard.2017.02.120
17. Lala A, Barghash M, Giustino G, et al. Early use of remote dielectric sensing after hospitalization to reduce heart failure readmissions. ESC Heart Fail. 2021;8(2):1047-54. https://doi.org/10.1002/ehf2.13026
18. Bensimhon D, Alali SA, Curran L, et al. The use of the reds noninvasive lung fluid monitoring system to assess readiness for discharge in patients hospitalized with acute heart failure: A pilot study. Heart Lung. 2021;50(1):59-64 https://doi.org/10.1016/j.hrtlng.2020.07.003
19. Ferguson M. Medical devices are different to pharmaceuticals in the Health Technology Assessment process. J Comp Eff Res. 2014;3(3):217-9. https://doi.org/10.2217/cer.14.17
20. O’Neill T, Miksad R, Miller D, Hornberger J. et al. ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products. Value Health. 2019;22(7):754-61. https://doi.org/10.1016/j.jval.2019.03.020
21. Habriev R, YAgudina R, Pravdyuk N. Ocenka tekhnologij zdravoohraneniya. Moscow, Medicinskoe informacionnoe agentstvo.2013;416.
22. Yagudina R, Kulikov A, Serpik V, Borodin A, Vygodchikova I. Patient Flows, Patient Distribution Computations and Medicines
Accounting in the Pharmacoeconomic Model Through Procurement Perspective. ClinicoEcon and Out Res. 2021;13:673-80. https://doi.org/10.2147/CEOR.S312986
23. Yagudina R, Kulikov A, Serpik V, Ugrekhelidze D. Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making.Value Health Reg Issues. 2017;3:61-6. https://doi.org/10.1016/j.vhri.2017.07.006
24. Conrads-Frank A, Schnell-Inderst P, Neusser S, et al. Decision-analytic modeling for Early health technology assessment of medical devices - a scoping review. Ger Med Sci. 2022;21:20. https://doi.org/10.3205/000313
25. Kulikov A, Serpik V, Protsenko M, Sobolev N. Health technology assessment of cataract phacoemulsification platforms. Phar: th and prac. 2019;7:4. https://doi.org/10.30809/phe.4.2019.2
26. Serpik V, Arsyutov D, Gulidova E, et al. Ékonomicheskie aspekty lecheniia diabeticheskogo makuliarnogo oteka na regional’nom urovne v Rossiĭskoĭ Federatsii [Economic aspects of diabetic macular edema treatment at regional level in Russian Federation]. Vestn Oftalmol. 2017;133(6):138-48. https://doi.org/10.17116/oftalma20171336138-148
27. Fomin I, Belenkov Y, Mareev V, et al. Rasprostranennost’ hronicheskoj serdechnoj nedostatochnosti v Evropejskoj chasti Rossijskoj Federacii — dannye EPOHA-HSN. Zhur serdech nedostat. 2006;7:112-5
28. Vinogradova N, Zhirkova M, Fomin I, Polyakov D. Effektivnost’ lecheniya HSN na ambulatornom etape v usloviyah gorodskogo centra HSN. Zhur serdech nedostat. 2017;18(4).
29. Gladkih A. Povtornye gospitalizacii i gospital’naya letal’nost’ u bol’nyh s hronicheskoj serdechnoj nedostatochnost’yu (dannye odnogodichnogo nablyudeniya). Moscow. 2009;26.
30. Vinogradova N. Cictema kompleksnogo podhoda k snizheniyu smertnosti i gospitalizacij v usloviyah specializirovannoj medicinskoj pomoshchi pacientam s hronicheskoj serdechnoj nedostatochnost’yu. Nizhnij Novgorod. 2020;293.
31. Guevarra J, et al. Retrospective evaluation of remote dielectric sensing (ReDS) vest technology and its impact on heart failure readmission rates and diuretics therapy. 2021.
32. Dispansernoe nablyudenie bol’nyh hronicheskimi neinfekcionnymi zabolevaniyami I pacientov s vysokim riskom ih razvitiya. Metodicheskie rekomendacii pod redakciej Bojcova S, Chuchalina A.
33. Yagudina R, Kulikov A, Serpik V. Farmakoekonomika. Rostov n/D,Feniks. 2018;237.
34. Seltzer J, Heise T, Carson P, Canos D, Hiatt J, Vranckx P, et al. Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium. Am Heart J. 2017;190:76-85. https://doi.org/10.1016/j.ahj.2017.05.009
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.